Edition:
United Kingdom

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

4.72USD
18 Apr 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$4.72
Open
$4.73
Day's High
$4.79
Day's Low
$4.58
Volume
55,649
Avg. Vol
105,662
52-wk High
$17.39
52-wk Low
$3.25

About

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen... (more)

Overall

Beta: --
Market Cap(Mil.): $639.40
Shares Outstanding(Mil.): 56.77
Dividend: --
Yield (%): --

Financials

  ACIU.OQ Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.69 -- --
ROI: -32.55 8.91 13.83
ROE: -33.72 10.06 15.25

Roche sees 2019 sales, profit rise despite competition from copies

ZURICH Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of its $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin, the Swiss drugmaker said on Thursday.

31 Jan 2019

Roche sees 2019 sales, profit rise despite competition from copies

ZURICH Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of its $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin, the Swiss drugmaker said on Thursday.

31 Jan 2019

UPDATE 2-Roche sees 2019 sales, profit rise despite competition from copies

* Forecasts new medicines to offset competition (Adds details throughout, comment from CEO)

31 Jan 2019

UPDATE 4-Roche, AC Immune drop Alzheimer drug trials after setback

* AC Immune shares plunge 65 percent (Adds AC Immune CEO commment, shares)

30 Jan 2019

Lilly partners with AC Immune for Alzheimer's treatment

U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

12 Dec 2018

UPDATE 1-Lilly partners with AC Immune for Alzheimer's treatment

Dec 12 U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

12 Dec 2018

Lilly partners with AC Immune for Alzheimer's treatment

Dec 12 Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer's disease.

12 Dec 2018

Earnings vs. Estimates